G7 Therapeutics is focused on stabilizing GPCRs for the discovery of novel medicines

G7 Therapeutics was acquired in November 2016 by Heptares Therapeutics to create a global leader in GPCR-targeted structure-based drug design and development. G7 Therapeutics will be renamed Heptares Zurich, Read press release here
Heptares Therapeutics

GPCRs, a family of integral membrane proteins, are the single largest class of drug targets and linked to the pathogenesis of many diseases. The discovery of drugs targeting GPCRs has been hampered by the instability of these receptors when removed from cells. Biophysical stabilisation of GPCRs by directed evolution technologies paves the way for innovative drug discovery technologies and structure-based drug design approaches to enable the creation of novel medicines for unmet medical needs.

News   Publications